Biology subjects

Nguyen, K. P.

Publications and source records attributed to Nguyen, K. P..

7 recordsLinked to original sources

bioRxiv2024

A high-throughput screening platform for discovering bacterial species and small molecules that modify animal physiology

Canonical polyamines such as agmatine, putrescine, and spermidine are evolutionarily conserved metabolites found in nearly all forms of life ranging from bacteria to humans. Recently, interactions between polyamines produced by gut bacteria and human intestinal cells have been proposed to contribute to both Irritable Bowel Syndrome with Diarrhea (IBS-D) and inflammatory bowel diseases. However, the molecular mechanisms that underlie these effects are often unclear due in part to limitations in the methods used to manipulate and study polyamine functions in vivo. Here, we developed a Caenorhabditis elegans based screening platform and a modified LC-MS approach for profiling polyamine metabolites. We combined these methods to make the unexpected discovery that dysfunctional polyamine metabolism in both Gram-negative (E. coli) and Gram-positive (B. subtilis) bacteria can result in the accumulation of a noncanonical polyamine intermediate, N1-Aminopropylagmatine (N1-APA). We further find that N1-APA is produced via spermidine synthase (SpeE) and that it is bioactive when encountered by animals. Specifically, we find that when N1-APA is produced by bacteria in animal intestines it can be transported into intestinal cells via the polyamine transporter CATP-5 where it antagonizes both animal development and mitochondrial function across diverse animal species. Lastly, we find that N1-APA functions analogously to the deoxyhypusine synthase inhibitor GC7. For example, like GC7, N1-APA antagonizes eIF5A hypusination and inhibits the alternative activation of mammalian macrophages. To our knowledge, these findings are the first to demonstrate that N1-APA is a bioactive metabolite and that bacteria can produce a small molecule that functions similarly to existing deoxyhypusine synthase inhibitors. Furthermore, these results suggest an exciting new mechanistic hypothesis for why the loss of speB in gut microbes, including E. coli, has been both linked to inflammatory bowel disease (IBD) in humans and found to drive IBD in germ free mice.

genetics↗

bioRxiv2022

The Indirect Pathway of the Basal Ganglia Promotes Negative Reinforcement, But Not Motor Suppression

Optogenetic stimulation of Adora2a receptor expressing spiny projection neurons (A2A-SPN) in the striatum drives locomotor suppression and negative reinforcement, results attributed to activation of the indirect pathway. The sole long-range projection target of A2A-SPNs is the external globus pallidus (GPe). Unexpectedly, we found that inhibition of the GPe did not suppress movement, but did drive robust negative reinforcement in a real-time place preference assay. Within the striatum, A2A-SPNs inhibit other SPNs through a short-range inhibitory collateral network, and we found that optogenetic stimuli that drove motor suppression shared a common mechanism of recruiting this inhibitory collateral network. Our results suggest that the indirect pathway plays a more prominent role in negative reinforcement than in motor control and challenges the assumption that activity of A2A-SPNs is synonymous with indirect pathway activity.

neuroscience↗

bioRxiv2021

Pitfalls and recommended strategies and metrics for suppressing motion artifacts in functional MRI

In resting-state functional magnetic resonance imaging (rs-fMRI), artefactual signals arising from subject motion can dwarf and obfuscate the neuronal activity signal. Typical motion correction approaches involve the generation of nuisance regressors, which are timeseries of non-brain signals regressed out of the fMRI timeseries to yield putatively artifact-free data. Recent work suggests that concatenating all regressors into a single regression model is more effective than the sequential application of individual regressors, which may reintroduce previously removed artifacts. This work compares 18 motion correction pipelines consisting of head motion, independent components analysis, and non-neuronal physiological signal regressors in sequential or concatenated combinations. The pipelines are evaluated on a dataset of cognitively normal individuals with repeat imaging and on datasets of studies of Autism Spectrum Disorder, Major Depressive Disorder, and Parkinsons Disease. Extensive metrics of motion artifact removal are measured, including resting state network recovery, Quality Control-Functional Connectivity (QC-FC) correlation, distance-dependent artifact, network modularity, and test-retest reliability of multiple rs-fMRI analyses. The results reveal limitations in previously proposed metrics, including the QC-FC correlation and modularity quality, and identify more robust motion correction metrics. The results also reveal limitations in the concatenated regression approach, which is outperformed by the sequential regression approach in the test-retest reliability metrics. Finally, pipelines are recommended that perform well based on quantitative and qualitative comparisons across multiple datasets and robust metrics. These new insights and recommendations help address the need for effective motion artifact correction to reduce noise and confounds in rs-fMRI.

bioengineering↗

bioRxiv2021

The BLENDS Method for Data Augmentation of 4-Dimensional Brain Images

PurposeData augmentation improves the accuracy of deep learning models when training data is scarce by synthesizing additional samples. This work addresses the lack of validated augmentation methods specific for synthesizing anatomically realistic 4D (3D+time) images for neuroimaging, such as fMRI, by proposing a new augmentation method. Materials and MethodsThe proposed method, BLENDS, generates new nonlinear warp fields by combining intersubject coregistration maps, computed using symmetric normalization, through spatial blending. These new warp fields can be applied to existing 4D fMRI to create new augmented images. BLENDS is tested on two neuroimaging problems using de-identified datasets: 1) the prediction of antidepressant response from task-based fMRI in the EMBARC dataset (n = 163), and 2) the prediction of Parkinsons Disease symptom trajectory from baseline resting-state fMRI regional homogeneity in the PPMI dataset (n = 43). ResultsBLENDS readily generates hundreds of new fMRI from existing images, with unique anatomical variations from the source images, that significantly improve prediction performance. For antidepressant response prediction, augmenting each original image once (2x the original training data) significantly increased prediction R2 from 0.055 to 0.098 (p < 1e-6), while at 10x augmentation R2 increased to 0.103. For the prediction of Parkinsons Disease trajectory, 10x augmentation R2 increased from 0.294 to 0.548 (p < 1e-6). ConclusionAugmentation of fMRI through nonlinear transformations with BLENDS significantly improves the performance of deep learning models on clinically relevant predictive tasks. This method will help neuroimaging researchers overcome dataset size limitations and achieve more accurate predictive models.

bioengineering↗

bioRxiv2020

Predicting Longitudinal Disease Severity for Individuals with Parkinson's Disease using Functional MRI and Machine Learning Prognostic Models

Parkinsons disease is the second most common neurodegenerative disorder and is characterized by the loss of ability to control voluntary movements. Predictive biomarkers of progression in Parkinsons Disease are urgently needed to expedite the development of neuroprotective treatments and facilitate discussions about disease prognosis between clinicians and patients. Resting-state functional magnetic resonance imaging (rs-fMRI) shows promise in predicting progression, with derived measures, including regional homogeneity (ReHo) and fractional amplitude of low frequency fluctuations (fALFF), having been previously been associated with current disease severity. In this work, ReHo and fALFF features from 82 Parkinsons Disease subjects are used to train machine learning predictors of baseline clinical severity and progression at 1 year, 2 years, and 4 years follow-up as measured by the Movement Disorder Society Unified Depression Rating Scale (MDS-UPDRS) score. This is the first time that rs-fMRI and machine learning have been combined to predict future disease progression. The machine learning models explain up to 30.4% (R2 = 0.304) of the variance in baseline MDS-UPDRS scores, 55.8% (R2 = 0.558) of the variance in year 1 scores, and 47.1% (R2 = 0.471) of the variance in year 2 scores with high statistical significance (p < 0.0001). For distinguishing high- and low-progression individuals (MDS-UPDRS score above or below the median), the models achieve positive predictive values of up to 71% and negative predictive values of up to 84%. The models learn patterns of ReHo and fALFF measures that predict better and worse prognoses. Higher ReHo and fALFF in regions of the default motor network predicted lower current severity and lower future progression. The rs-fMRI features in the temporal lobe, limbic system, and motor cortex were also identified as predictors. These results present a potential neuroimaging biomarker that accurately predicts progression, which may be useful as a clinical decision-making tool and in future trials of neuroprotective treatments.

neuroscience↗

bioRxiv2020

Distinct Predictive Patterns of Antidepressant Response to Sertraline, Placebo and Bupropion using Pre-Treatment Reward Processing as examined through Functional MRI and Deep Learning: Key Results from the EMBARC Study

ImportanceThe lack of antidepressant-specific biomarkers to inform treatment selection is a key obstacle in the treatment of Major Depressive Disorder. Quantitative measurements of reward processing neural activity with task-based functional magnetic resonance imaging (fMRI) may allow prediction of individual outcomes for specific antidepressants. ObjectiveTo build and validate predictors of individual outcomes for sertraline, bupropion, and placebo using reward processing task-based fMRI, clinical assessments, and deep learning. DesignThis is a secondary analysis of data from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study, a placebo-controlled, double-blind randomized clinical trial. The study ran from July 2011 to December 2015 and this analysis was performed between December 2018 and July 2019. SettingThe EMBARC study was conducted at 4 academic medical centers. ParticipantsA random sample of 296 un-medicated participants meeting DSIM-IV criteria for depression was enrolled. InterventionSubjects were randomized to sertraline or placebo during phase 1. In phase 2, non-responders to placebo were treated with sertraline and non-responders to sertraline were treated with bupropion. Each phase lasted for 8 weeks. Main outcomes and measuresThe primary outcome was the change in the 17-item Hamilton Rating Scale for Depression ({Delta}HAMD) after 8 weeks of treatment. Task-related brain activation measures, computed from pre-treatment reward processing task fMRI, and clinical measurements were used to train deep learning predictive models for each treatment group. ResultsThe current analysis includes 222 participants with complete imaging, clinical, and treatment outcome data (146 female, mean age 16.4 {+/-} 13.4 years). The predictive model for sertraline, trained on 106 participants, achieved an R2 of 35% (95% CI 20-50%, p < 10-3) in predicting {Delta}HAMD and a number-needed-to-treat (NNT) of 4.31 in predicting remission. The placebo model, trained on 116 participants, achieved an R2 of 23% (95% confidence interval of 11-37%, p < 10-3) and an NNT of 2.78. The bupropion model achieved an R2 of 37% (95% CI 12-61%, p < 10-3) and an NNT of 2.35. Reward processing activity in regions such as the medial frontal cortex, insula, and thalamus were important predictors of sertraline outcome, while the anterior cingulate cortex, striatum, insula, and thalamus were important regions for predicting bupropion outcome. These are consistent with previously reported findings, while regions not previously implicated such as the temporal pole and paracentral lobule were also found to be predictive. Conclusions and relevanceThese findings demonstrate the utility of reward processing measurements and deep learning in predicting individual antidepressant outcomes with high accuracy. They also present potential composite biomarkers for these treatments based on neuroimaging and clinical features. Trial registrationClinicalTrials.gov identifier: NCT01407094 KEY POINTSO_ST_ABSQuestionC_ST_ABSCan pre-treatment fMRI measurements of reward processing, in combination with multi-dimensional clinical assessments, be used to form personalized predictions of antidepressant outcomes? FindingsDeep learning predictive models trained on pre-treatment reward processing task-based neuroimaging and clinical data from a randomized clinical trial were able to explain up to 37% of the variance in individual treatment outcomes and predict remission with NNT of 2-4. Specific clinical variables and brain regions with reward processing activity important for the model predictions were identified, which may form composite biomarkers of antidepressant response. MeaningQuantitative measures of reward processing, as identified through deep learning, may move us closer to a precision medicine approach that enables clinicians to select the appropriate antidepressant for each patient with greater certainty.

bioinformatics↗

bioRxiv2018

Optimizing sequential decisions in the drift-diffusion model

To make decisions organisms often accumulate information across multiple timescales. However, most experimental and modeling studies of decision-making focus on sequences of independent trials. On the other hand, natural environments are characterized by long temporal correlations, and evidence used to make a present choice is often relevant to future decisions. To understand decision-making under these conditions we analyze how a model ideal observer accumulates evidence to freely make choices across a sequence of correlated trials. We use principles of probabilistic inference to show that an ideal observer incorporates information obtained on one trial as an initial bias on the next. This bias decreases the time, but not the accuracy of the next decision. Furthermore, in finite sequences of trials the rate of reward is maximized when the observer deliberates longer for early decisions, but responds more quickly towards the end of the sequence. Our model also explains experimentally observed patterns in decision times and choices, thus providing a mathematically principled foundation for evidence-accumulation models of sequential decisions.

neuroscience↗